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Abstract
Background Saquinavir/ritonavir (1000/100 mg twice
daily [BID]) is associated with dose- and exposure-de-
pendent prolongation of the QT interval. The QT risk is
considered higher during the first week of therapy, when
saquinavir peak exposure has been observed. A modified
regimen with a lower dose lead-in phase may reduce po-
tential saquinavir-/ritonavir-induced QT prolongations.
Objective To explore the effect of the modified saquina-
vir/ritonavir regimen on QT interval, pharmacokinetics,
antiviral activity, and safety in treatment-naı¨ve HIV-1-in-
fected patients.
Methods Twenty-three HIV-1-infected treatment-naı¨ve
patients received saquinavir/ritonavir 500/100 mg BID on
days 1–7 and 1000/100 mg BID on days 8–14 in combi-
nation with two nucleoside reverse transcriptase inhibitors.
The primary endpoint was mean maximum change from
dense predose baseline in QT values corrected using
Fridericia’s formula (DQTcFdense) across study days. Se-
condary endpoints included maximum change from time-
matched baseline in QTcF, antiviral activity, pharmacoki-
netics, and safety over the 14 days.
Results The mean maximum DQTcFdense was 3, 1, 7, 12,
and 7 ms on days 3, 4, 7, 10, and 14, respectively. Across
all study days, 2/21 patients had a maximum DQTcFdense
C30 ms (on day 10); the highest mean DQTcFdense was
\10 ms. During week 1, saquinavir exposure was highest
on day 3 and lowest on day 7. All patients showed con-
tinuous declines in HIV-RNA; none experienced virologic
breakthrough/rebound. The modified regimen was gener-
ally well tolerated.
Conclusion Treatment initiation with the modified
saquinavir/ritonavir regimen in treatment-naı¨ve HIV-1-in-
fected patients reduced saquinavir exposure during week 1,
potentially mitigating/reducing QT liability while sup-
pressing HIV-RNA during the course of treatment.
M. C. Abelardo: Working in private stem-cell/regenerative medicine
research.
M. Boffito  A. Jackson  A. Pozniak
Chelsea and Westminster Hospital NHS Foundation Trust,
London, UK
M. Giraudon
F. Hoffmann-La Roche Ltd, Basel, Switzerland
R. Kulkarni  M. C. Abelardo
Genentech, South San Francisco, CA, USA
Present Address:
R. Kulkarni
Guardian Analytics, San Francisco, CA, USA
I. H. Patel  P. N. Morcos
Hoffmann-La Roche Inc., Nutley, NJ, USA
P. N. Morcos (&)
Roche Innovation Center New York, 430 East 29th St,
New York, NY 10016, USA
e-mail: peter.morcos@roche.com
Drugs R D (2015) 15:141–153
DOI 10.1007/s40268-015-0087-7
Key Points
QT prolongation by protease inhibitors, including
saquinavir, has been demonstrated to be a result of
dose-dependent blockage of the human ether-a-go-
go-related gene (hERG) channels.
A modified saquinavir/ritonavir dosage regimen is
recommended in the EU for treatment-naı¨ve patients
initiating therapy (500/100 mg twice daily for the
first 7 days, then 1000/100 mg twice daily
thereafter). This modified regimen is predicted to
reduce the risk of saquinavir-associated QT
prolongation in the first week of treatment.
The results of this trial demonstrate that treatment
initiation with the modified saquinavir/ritonavir is
associated with reduced saquinavir exposure during
the first week, potentially mitigating or reducing QTc
liability while suppressing HIV RNA levels.
1 Introduction
In 1995, saquinavir became the first HIV-1 protease in-
hibitor approved for the treatment of HIV-1 infection, and
it was subsequently approved in combination with low-
dose ritonavir in the member states of the European Union
and in a number of other countries. The oral bioavailability
of saquinavir is limited by extensive first-pass metabolism,
mediated primarily by cytochrome P450 3A4 enzyme
(CYP3A4) [1]. Coadministration of low-dose ritonavir,
another protease inhibitor that is also a potent inhibitor of
CYP3A4 and P-glycoprotein [2], increases saquinavir
bioavailability and exposure, thereby improving therapeu-
tic efficacy. The approved recommended therapeutic dose
in the US and Europe for adults is saquinavir 1000 mg
twice daily (BID) in combination with ritonavir 100 mg
BID. The efficacy and safety of saquinavir/ritonavir
1000/100 mg BID have been demonstrated in several large
phase III clinical trials [3, 4] and, since its approval in
1995, approximately 1,200,000 patients have received
saquinavir (Roche, personal communication).
There is uncertainty in the literature as to whether there
is an effect of HIV protease inhibitors on cardiac conduc-
tivity as measured by prolongation of QT and PR interval
durations. Despite this apparent uncertainty, the results of a
previous TQT study in healthy subjects demonstrated sig-
nificant dose-dependent QT and PR interval prolongation
with therapeutic and supratherapeutic doses of saquinavir/
ritonavir 1000/100 mg BID and 1500/100 mg BID,
respectively [5]. In response to the findings of the TQT
study and risk of significant QT prolongation in the first
week of treatment with saquinavir/ritonavir 1000/100 mg
BID, the recommended dosing regimen for treatment-naı¨ve
patients initiating ritonavir-boosted saquinavir therapy was
amended in 2011 by the European Medicines Agency. The
revised European label recommends that treatment-naı¨ve
patients initiate therapy with saquinavir/ritonavir at a
dosage of 500/100 mg BID for the first 7 days followed by
the standard dosage of saquinavir/ritonavir 1000/100 mg
BID thereafter [6]. No changes to dosing recommendations
were requested by the US FDA. The current study was
carried out at the request of the European Medicines
Agency to explore the effect of the modified saquinavir/
ritonavir regimen (500/100 mg BID on days 1–7 followed
by 1000/100 mg BID on days 8–14) on the QTc interval,
pharmacokinetics, antiviral activity, and safety in treat-
ment-naı¨ve HIV-1-infected patients.
2 Methods
This single-center, open-label, multiple-dose, single-arm
study was conducted between January and June 2012
(ClinicalTrials.gov number NCT01638650). The primary
objective of the study was to measure the maximum change
from dense predose baseline in QTcF (DQTcFdense) (see
Sect. 2.4). Secondary objectives included the collection of
information on the pharmacokinetics, antiviral activity, and
safety of the modified saquinavir/ritonavir regimen and to
evaluate the effect of this regimen on other electrocardio-
gram (ECG) parameters (heart rate, RR interval, QT in-
terval, PR interval, QRS interval). Exploratory analyses
were also planned to explore the relationship, if any, be-
tween changes in QTc interval and saquinavir plasma
concentrations.
2.1 Patients
HIV-1-infected treatment-naı¨ve patients who were at least
18 years of age were included in the study if they were
eligible and willing to initiate a saquinavir (Invirase; F.
Hoffmann-La Roche, Basel, Switzerland) plus ritonavir
(Norvir; Abbott, Chicago, IL, USA) regimen in combi-
nation with two nucleoside reverse transcriptase inhibitors
(NRTIs), in accordance with current clinical HIV treatment
guidelines at the time of the study, for the first 14 days, and
had a body mass index (BMI) of 18–32 kg/m2, HIV-1 RNA
levels below 500,000 copies/mL, CD4? T lymphocyte
count above 200 cells/mm3, and a resting heart rate of
50–100 beats per minute, and had not smoked tobacco
products for at least 3 months prior to day 1 of the study.
Patients were excluded if they were co-infected with
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hepatitis B or C virus, if they had received (4 weeks prior
to baseline [day -1]) medications known to alter cardiac
conduction, interfere with the human ether-a-go-go-related
gene (hERG) channel or to be associated with QT pro-
longation, if they were receiving medications that had the
potential to interact with saquinavir or ritonavir, if they had
a cardiac pacemaker, or if they had screening or baseline
ECG abnormalities or were at increased risk of ECG ab-
normalities because of electrolyte disturbances, if they had
a history or evidence of symptomatic arrhythmias, long QT
syndrome, atrial fibrillation or flutter, complete right or left
bundle branch block, or Wolff–Parkinson–White
syndrome.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and good clinical
practice guidelines. The study was approved by the Inde-
pendent Ethics Committee, London–Riverside Research
Ethics Committee, Bristol, United Kingdom and the
European Committee for Medicinal Products for Human
Use (CHMP). All patients provided written informed
consent.
2.2 Study Design
Patients reported to the study unit on the evening before
baseline and before study days 3, 7, 10, and 14 and re-
mained at the study unit until the completion of last ECG
assessment specified for each study day (34–38 h to cover
both baseline and day 1, 46–50 h to cover both days 3 and
4, and 22–26 h for days 7, 10, and 14). All patients re-
ceived the modified saquinavir/ritonavir regimen (500/
100 mg BID on days 1–7 followed by 1000/100 mg BID
on days 8–14). Study medications were to be taken with
240 mL of water, 15–30 min after the consumption of a
meal. On days 3, 4, 7, 10, and 14, a standardized breakfast
was provided 45 min prior to the morning dosing. On days
3, 4, 7, 10, and 14, a standard lunch was provided 15 min
after the 4-h ECG extraction time point, and a standard
dinner was provided 15 min after the 12-h extraction time
point. Meals were to be completed within 20–30 min.
During the stay at the study unit, the scheduled saquinavir/
ritonavir doses were administered by the study staff; dosing
on other study days was administered by the patients. Pa-
tients received study medications in combination with two
NRTIs (tenofovir/emtricitabine). Fluid intake, meals, en-
vironment, and physical activity level remained as con-
trolled and as consistent as possible during the specified
stay at the study unit.
Subjects maintained a study diary that tracked their
meals and study drug administration. Additionally, subjects
had stays in the phase I unit on days 1–4, 7, 10, and 14,
where they were monitored by the study staff. Subject
compliance to study medications was assessed by
maintaining adequate study drug dispensing records. The
investigator was responsible for ensuring that dosing was
administered in compliance with the protocol and for fol-
lowing up with study volunteers.
2.3 Assessments
2.3.1 Electrocardiograms (ECGs)
The primary and secondary endpoints were determined by
analysis of digital ECG data by cardiologists. All scheduled
ECGs were performed after the patients had rested for at
least 10 min in a supine position. Continuous Holter
12-lead ECG recordings (Mortara H-12?TM digital Holter
recorder, Mortara Instruments, Inc. Milwaukee, WI, USA)
were obtained at baseline from -25 h predose up to
-11.75 h predose, on day 1 from -1.5 h predose up to 1 h
postdose, and on days 3, 4, 7, 10, and 14 from -1 h pre-
dose up to 12.25 h postdose.
These data were forwarded to a central laboratory for
evaluation (Cardiocore, Rockville, MD, USA). After de-
livery of the Holter data, replicate 12-lead ECG recordings
that were 10 s in duration and corresponded to specific
time points after dosing (2, 4, 6, 8, and 12 h), were ex-
tracted to determine the primary and secondary end-points
in the study.
The digital (Holter monitor data) ECGs were reviewed
for each patient by the same team of two cardiologists to
control variability in interpretation. All measurements were
blinded with respect to time, treatment, and subject iden-
tifier. The following intervals were measured and recorded:
heart rate, RR, PR, QRS, and QT intervals. The ECG
machine provided corrected QT intervals (QTc), and, for
each subject and extraction point, the QTc values were
corrected using Bazett’s formula (QTcB) and Fridericia’s
formula (QTcF). T- and U-wave morphology was also
assessed using predefined criteria. T waves were labelled
abnormal if they were inverted, flat, biphasic, peaked, had
non-specific changes, or were considered to be altered due
to ventricular conduction or due to left ventricular hyper-
trophy. If present, U waves were labelled as normal or
abnormal, and abnormal U waves were described as being
large, inverted or fusion of T–U waves/early after depo-
larization. ECG intervals were analysed semi-auto-
matically: fiducial points were placed by an algorithm and
then confirmed or adjusted by the cardiologist as recom-
mended by the International Conference on Harmonisation
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use [7].
The Holter monitor data were not available to study
personnel to determine eligibility or monitor safety. Thus,
triplicate paper ECGs were recorded within 10 min of each
other (3–5 min apart) once at screening, on day -2, and at
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follow-up (3–7 days after last dose) to determine eligibility
and monitor safety. The paper ECGs were not forwarded to
Cardiocore, were not seen by the cardiologists, and were
not used to determine the primary or secondary end-points
in the study.
2.3.2 Pharmacokinetics
Blood samples (3 mL) for measurements of plasma
saquinavir and ritonavir concentrations were collected
from all patients predose and at 2, 4, 6, 8, and 12 h post-
dose on days 3, 4, 7, 10, and 14, and analyzed using
validated liquid chromatography with tandem mass spec-
trometry detection methods (range 50.0–10,000 ng/mL) as
described previously [5]. For saquinavir, assay precision
based on the quality control samples ranged from ±4.6 to
7.4 % while accuracy ranged from -0.7 to 2.1 %. For ri-
tonavir, assay precision based on quality control samples
ranged from ±3.3 to 3.4 % and accuracy ranged from -1.3
to 4.0 %.
2.3.3 Pharmacodynamics (antiviral activity)
Blood samples (5 mL) were collected for HIV RNA
quantification at predose on days 1, 3, 4, 7, 10, and 14. The
total volume of blood required for the HIV RNA testing
was approximately 35 mL per patient. HIV RNA quan-
tification was performed using a validated, commercial
polymerase chain reaction-based assay (COBAS Am-
pliPrep/COBAS TaqMan HIV-1 Test).
2.3.4 Safety
All patients who received at least one dose of the study
medication were included in the safety population and were
assessed by monitoring ECGs, vital signs, laboratory tests,
and adverse events (AEs) throughout the study. AEs were
graded on a 3-point scale (mild, moderate, and severe). Pa-
tients with ECGs showing a significant increase in QT/QTc
([500 ms or [60 ms from baseline) that persisted for an
hour or more were withdrawn from the study and ECG
recordings were repeated until two successive ECGs showed
QTc values below the threshold value of the initial increase.
2.4 Statistical Methods
No formal sample size calculation was performed. The
sample size was based on practical considerations and
discussions with regulatory agencies. All patients who re-
ceived at least one dose of study medication were included
in the ECG analysis. For all ECG variables, the average of
the triplicate measurements obtained at each time point was
used as a single observation. The primary endpoint was the
maximum change from dense predose baseline in QTcF
(DQTcFdense) at time points 2, 4, 6, 8, and 12 h postdose on
days 3, 4, 7, 10, and 14. The dense predose baseline was
defined as the average of the three triplicate measurements
(nine measurements overall collected at 1, 0.75, and 0.5 h
predose on day 1). This is identical to the dense predose
baseline measurement as defined in the previous QT study
of saquinavir in healthy volunteers [5]. Maximum
DQTcFdense was described using summary statistics. Se-
condary ECG variables included absolute and change from
baseline in QT, QTcB, RR, heart rate, PR, QRS, T-wave,
and U-wave at the same time points defined above. In
addition, maximum change from time-matched baseline in
QTcF (DQTcFtmcb) was also used as a secondary variable
to measure the maximal increase in baseline-corrected
QTcF.
All patients treated and adherent to the protocol were
included in the pharmacokinetics and pharmacodynamics
analysis. The trough drug concentration, defined as the
concentration at the end of the dosing interval (C12),
maximum concentration (Cmax), time to reach Cmax (tmax),
and area under the plasma concentration–time curve from 0
to 12 h (AUC0–12h) for saquinavir and ritonavir, were es-
timated using noncompartmental methods using WinNon-
lin software (version 5.2, Pharsight Corporation, Mountain
View, CA, USA) for days 3, 4, 7, 10, and 14. Pharma-
cokinetics measurements were presented by descriptive
summary statistics. Predose actual sampling times were set
to zero. Actual sampling times were used for the non-
compartmental analyses and for the individual plasma
concentration versus time profiles. Scheduled sampling
times were used for the creation of summary tables and
mean plasma concentration versus time profiles. Individual
and mean serum HIV RNA levels at each sampling time
point were described by summary statistics. Changes from
baseline in HIV RNA in plasma on days 3, 4, 7, 10, and 14
were calculated.
3 Results
3.1 Patient Disposition and Demographics
Twenty-three patients enrolled in the study, all of whom
were male and most of whom were White (83 %). The
mean age was 33 ± 9 years, mean BMI was 24 ± 3 kg/
m2, and mean baseline HIV RNA was 4.69 ± 0.47 log10
copies/mL. Twenty-one patients completed the study as
planned; one patient discontinued due to a non-drug-related
serious adverse event (gonococcal proctitis), and one pa-
tient withdrew consent.
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3.2 ECG Evaluation
Available ECG data from all 23 patients enrolled in the
study were included in the analyses. For the two patients
who withdrew from the study, no ECG data were available
for one patient after day 3 predose and for one patient after
day 3 at 8 h predose. The modified saquinavir/ritonavir
regimen was associated with a mean maximum
DQTcFdense of 3, 1, 7, 12, and 7 ms on days 3, 4, 7, 10, and
14, respectively (Table 1). The mean maximum
DQTcFtmcb was slightly higher than the mean maximum
DQTcFdense but followed a similar pattern. Only 9.5 % (2/
21) and 19 % (4/21) of patients demonstrated a maximum
DQTcFdense C30 ms and DQTcFtmcb C30 ms, respectively,
across all study days, but all were\60 ms (Table 1). Only
one patient had an absolute QTcF of [450 ms but
\480 ms. This individual had an absolute QTcF of
454 ms on day 10 at predose which subsequently declined
to 428 ms 2 h postdose. No patient had an absolute QTcF
of [500 ms.
The maximum mean changes from baseline for
QTcFdense and QTcFtmcb were highest on day 10, but re-
mained below 10 and 12 ms, respectively, at all time
points (Table 1; Fig. 1).
Maximum mean DQTcFdense and DQTcFtmcb were 9 and
12 ms, respectively, at 6 h postdose on day 10.
Maximum changes from dense predose and time-mat-
ched baselines were observed at 6 h postdose for heart
rate, RR interval, and QT interval, and at 4 h postdose for
PR interval (data not shown). However, these ECG pa-
rameters, including QRS interval, were not affected by
treatment with saquinavir/ritonavir at either 500/100 mg
BID or 1000/100 mg BID and changes were small and not
clinically significant.
The mean maximal changes in secondary ECG pa-
rameters (heart rate, RR, PR, QRS and QT intervals) are
presented in Table 2.
3.3 Pharmacokinetic Analysis and Effect on QTcF
The mean (±standard deviation) plasma concentration–
time profiles of saquinavir and ritonavir throughout the
study are shown in Fig. 2 and key pharmacokinetic pa-
rameters are summarized in Table 3. Following adminis-
tration of saquinavir/ritonavir 500/100 mg BID during the
first 7 days, the mean saquinavir plasma concentrations
peaked on day 3 and declined on days 4 and 7, with the
lowest concentrations observed on day 7. Doubling the
dose of saquinavir to the standard dose of 1000/100 mg
BID during the second week resulted in higher mean
saquinavir plasma concentrations on day 10, as expected,
with only slightly lower mean saquinavir plasma concen-
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mean plasma concentrations, the highest saquinavir mean
Cmax and AUC0–12h following administration of saquinavir/
ritonavir 500/100 mg BID was observed on day 3
(4030 ng/mL and 27,100 ngh/mL, respectively) and de-
clined on days 4 and 7, with the lowest exposure on day 7.
Similarly, doubling the dose of saquinavir to 1000/100 mg
BID during the second week resulted in higher mean Cmax
and AUC0–12h on days 10 and 14 with highest Cmax and
AUC0–12h on day 10 (5300 ng/mL and 34,200 ngh/mL,
respectively). Median time to Cmax (i.e., Tmax) for saqui-
navir was reached approximately 2–4 h after dosing
(Table 3).
Mean ritonavir plasma concentrations and mean riton-
avir exposures (Cmax and AUC0–12h) fluctuated across
study days but were generally similar when considering the
interindividual variability (Table 3). Highest mean riton-
avir plasma concentrations were observed on day 3 while
the lowest mean ritonavir plasma concentrations were ob-
served on day 7, coinciding with the lowest observed
saquinavir exposure (Table 3; Fig. 2). Median Tmax was
reached approximately 3–4 h after dosing (Table 3). The
pharmacokinetics of ritonavir generally appeared to be
independent of saquinavir exposure.
The relationship between saquinavir concentration and
QTcF was evaluated using Cmax because a delay in max-
imum DQTcFdense compared with maximum saquinavir
plasma concentrations is observed manifesting as a coun-
ter-clockwise hysteresis (data not shown). No strong cor-
relation was observed between the maximum DQTcFdense
and Cmax of saquinavir (Fig. 3).
3.4 Pharmacodynamics
Individual patients’ HIV RNA profiles are illustrated in
Fig. 4. Continuous declines in HIV RNA were observed in
all treatment-naı¨ve patients receiving the modified saqui-
navir/ritonavir regimen over the 14-day treatment period.
The mean HIV RNA level declined from 4.69 ± 0.47 log10
copies/mL at baseline to 2.83 ± 0.48 log10 copies/mL


















































Fig. 1 Change from a dense
predose and b time-matched
baselines in QT values corrected
using Fridericia’s formula
(QTcF). Line plots represent
mean change (SEM) over time.
Box plots represent distribution
of maximum change from
baseline in QTcF by study day.
Solid horizontal bars indicate
median values; solid dots
indicate mean values; boxes
indicate interquartile ranges;
vertical dotted lines (whiskers)
indicate maximum and
minimum values; open circles
indicate outliers. Chb change
from baseline
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-1.93 ± 0.28 log10 copies/mL on day 14 (Table 4). No
resistance testing was conducted, since no patient experi-
enced either a viral breakthrough (detectable HIV RNA
after undetectable HIV RNA) or viral rebound (increase in
HIV RNA following a decline in HIV RNA).
3.5 Safety
All patients enrolled in the study were included in the
safety analysis. The modified saquinavir/ritonavir regimen
was generally well tolerated. There were no deaths during
the study. One patient discontinued study drug due to
gonococcal proctitis which was classified as a serious AE
but was not considered to be drug-related. A total of 55
treatment-emergent AEs were reported during the study, of
which most were mild (37; 67 %) or moderate (16; 29 %)
in severity. Only two events were considered to be severe
(one case of lethargy and one case of gonococcal proctitis;
each in one patient). The most commonly reported AEs
(reported by C10 % of patients) during the study were
diarrhea (48 %), nausea (35 %), headache (35 %), vomit-
ing (22 %), and lethargy (13 %).
There were no clinically meaningful changes in mean
values of laboratory chemistry parameters or mean vital
sign values during the study.
4 Discussion
This study was conducted to determine the effect of the
modified saquinavir/ritonavir regimen (500/100 mg BID
for the first week followed by 1000/100 mg BID for the
second week) on the QTc interval, pharmacokinetics, an-
tiviral activity, and safety in treatment-naı¨ve HIV-1-in-
fected patients. The rationale for the study, study design,
and dosing regimen was to assess the impact of a change in
the saquinavir/ritonavir dosing in treatment-naı¨ve patients
as recommended by the European Medicines Agency [6].
In a previous TQT study in healthy volunteers, the
maximum least-squares mean estimated study-specific QTc
(QTcS) change from predose baseline (ddQTcSdense) was
19 ms at 12 h postdose with a saquinavir/ritonavir
1000/100 mg BID regimen, and 30 ms at 20 h postdose
with a 1500/100 mg BID regimen on day 3 of treatment
with saquinavir/ritonavir BID compared with 12 ms 4 h
after a single 400 mg dose of the positive control
moxifloxacin [5]. Day 3 was selected for evaluation in the
healthy volunteer TQT study based on another completed
healthy volunteer multiple ascending dose (MAD) study,
which showed that saquinavir exposure would be highest
on day 3 of treatment with saquinavir/ritonavir and would
decline with further administration [8]. A post hoc phar-
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pharmacokinetic and QTc data from the TQT study
demonstrated a linear exposure–response relationship be-
tween ddQTcSdense and Cmax (Roche, personal communi-
cation). Based on this relationship, a modified saquinavir/
ritonavir dosing regimen of 500/100 mg BID for the first
7 days followed by the full therapeutic dose regimen
(1000/100 mg BID) thereafter in treatment-naı¨ve patients
was expected to reduce QTc liability while maintaining
efficacy with regard to concentration/exposure and conse-
quently virologic suppression.
QTc results for the primary endpoint from this study
(maximum DQTcFdense) illustrated that the modified
saquinavir/ritonavir regimen resulted in a mean maximum
DQTcFdense of 3 ms on day 3 with mean values peaking at
12 ms on day 10. Some day-to-day fluctuations were ob-
served in mean maximum DQTcFdense that may be due to
the observed high interpatient variability. It is also im-
portant to note that in vitro experiments have demonstrated
that saquinavir results not only in dose-dependent blockage
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Visit Day 3 Day 4 Day 7 Day 10 Day 14
Fig. 2 Mean plasma
concentration–time profiles
following administration of the
modified saquinavir/ritonavir
regimen for a saquinavir and
b ritonavir
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cells, but also has inhibitory effects on hERG trafficking [9,
10]. Thus, a potentially complex contribution/interplay
between direct hERG blocking and hERG trafficking by
saquinavir may potentially contribute to the day-to-day
variability seen in mean maximum DQTcFdense. Impor-
tantly, only 2/21 (9.5 %) patients had a maximum
DQTcFdense C30 ms, which occurred on day 10. The
maximum mean DQTcFdense was less than 10 ms across all
sampling days. Secondary analyses using QTcFtmcb
illustrated trends similar to the primary analysis using
QTcFdense, though values were slightly larger, potentially
due to the baseline correction used and any consideration
of diurnal variations. The results from the present study
confirm and extend the results from the TQT study in
healthy volunteers, although the primary endpoints differ in
the two studies [5]. In the TQT study, in healthy volunteers
the mean maximum DQTcFdense (a secondary endpoint in
the TQT study) with the full therapeutic dose (1000/
Table 3 Summary of pharmacokinetic parameters following administration of the modified saquinavir/ritonavir regimen in HIV-1-infected
patients
Drug Day 3 Day 4 Day 7 Day 10 Day 14
AUC0–12h ngh/mL, mean ± SD Saquinavir 27,100 ± 9650 20,300 ± 8100 12,600 ± 6850 34,200 ± 16,500 31,100 ± 15,400
Ritonavir 14,400 ± 5940 11,600 ± 4930 9670 ± 3520 11,500 ± 3510 10,400 ± 3580
Cmax ng/mL, mean ± SD Saquinavir 4030 ± 1170 2960 ± 1190 1960 ± 1040 5300 ± 1910 4860 ± 2270
Ritonavir 2130 ± 843 1720 ± 690 1410 ± 600 1800 ± 675 1620 ± 615
Tmax h, median (range) Saquinavir 1.98 (1.98–6.02) 3.98 (0–7.98) 3.98 (0–7.98) 3.98 (1.98–7.98) 3.98 (1.98–5.98)
Ritonavir 2.98 (0–5.98) 3.98 (0–5.98) 3.98 (0–7.98) 3.98 (1.98–7.98) 3.98 (1.98–5.98)
C12 ng/mL, mean ± SD Saquinavir 899 ± 583 782 ± 488 416 ± 409 1220 ± 1120 1120 ± 910
Ritonavir 476 ± 309 401 ± 208 322 ± 162 336 ± 167 346 ± 159
AUC0–12h area under the plasma concentration-time curve from 0–12 h, C12 trough drug concentration, Cmax maximum observed plasma








































profile for change from dense
predose baseline in QT values
corrected using Fridericia’s
formula (QTcF)
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100 mg BID) was 32 ms and occurred on day 3 (Roche,
personal communication). Fifty-one percent of the
population receiving the full therapeutic dose had a
DQTcFdense of [30 ms (Roche, personal communication).
The results of both studies taken together suggest that the
profile of QTc prolongation is beneficially impacted with
the modified saquinavir/ritonavir dosing regimen that re-
duces saquinavir exposure in the first week; however, it is
important to note how differences in study designs, study






















Day 1 –0.5 H Day 3 –0.75 H Day 4 –0.75 H Day 7 –0.75 H Day 10 –0.75 H Day 14 –0.75 H
Treatment: SQVr 500/100 mg (D1 - D7)/SQVr 1000/100 mg (D8 - D14) / N=23






























Baseline Day 3 -0.75 H Day 4 -0.75 H Day 7 -0.75 H Day 10 -0.75 H Day 14 -0.75 H
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Fig. 4 a Absolute and b change
from baseline log10 HIV RNA
of individual patients across the
study
Table 4 Effect of the modified saquinavir/ritonavir regimen on log10 HIV RNA in HIV-1-infected patients
Baseline Day 3 Day 4 Day 7 Day 10 Day 14
Mean log10 HIV RNA ± SD 4.69 ± 0.47 4.46 ± 0.49 4.12 ± 0.51 3.42 ± 0.56 3.13 ± 0.49 2.83 ± 0.48
Change from baseline, mean ± SD – -0.24 ± 0.22 -0.64 ± 0.26 -1.35 ± 0.31 -1.63 ± 0.29 -1.93 ± 0.28
SD standard deviation
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comparisons between studies. Also, notably, no placebo- or
positive-control treatment was included in the current
study.
Limitations of the present study include the small
number of patients, the lack of a control group, the absence
of female participants and the low number of non-White
participants. The results of both the present study and the
earlier healthy volunteer study by Zhang and colleagues [5]
support the evidence that saquinavir is associated with QT
interval prolongation despite the considerable uncertainty
and contradictory reports in the literature on the effect of
the HIV protease inhibitor class of antiretrovirals on car-
diac repolarization. It is not entirely clear why there are
contradictory reports in the literature, but it is possible that
the effect of protease inhibitors on cardiac repolarization is
seen predominantly during the first few days or weeks of
treatment (as seen in the TQT studies) as opposed to cross-
sectional studies of patients on chronic therapy. However,
QT interval prolongation and torsades de pointes are rare
events among the large number of patients receiving HIV
protease inhibitor therapy, including those treated with
saquinavir. Furthermore, it has been reported that duration
of HIV infection is independently associated with QT in-
terval prolongation [11] and that risk factors for QT in-
terval prolongation for HIV patients are similar to those
seen in non-HIV-infected patients, including factors such
as age, female sex, ethnicity, cardiac conditions, diabetes
mellitus, and use of drugs known to cause QT interval
prolongation [12]. However, the clinical consequences of
such prolongation remain unclear.
Pharmacokinetic data from this study showed that fol-
lowing administration of the modified saquinavir/ritonavir
dose regimen of saquinavir/ritonavir 500/100 mg BID in
the first week, mean saquinavir exposure peaked on day 3
and declined to the lowest exposure on day 7 as expected
with ritonavir induction effects. Moreover, saquinavir ex-
posure in the first week of treatment with the modified
saquinavir/ritonavir dosing regimen in the present study
was substantially lower than that observed on day 3 of
treatment with the full therapeutic dose (1000/100 mg
BID) in the healthy volunteer TQT study [5]. Following
administration of the full saquinavir/ritonavir dose in the
second week, saquinavir exposure was higher on days 10
and 14 compared with the first week, as expected, and was
slightly lower on day 14 compared with day 10, suggesting
a continued decline in saquinavir exposure toward steady
state. This is consistent with results from the healthy vol-
unteer MAD study, which showed that mean saquinavir
predose concentrations were slightly lower on day 14
compared with day 10 [8]. Day 14 pharmacokinetic pa-
rameters approached the range of historical means for
saquinavir steady-state values in HIV-1-infected patients
[13–20].
The observed mean saquinavir exposure (AUC and C12)
following the modified saquinavir/ritonavir regimen ex-
ceeded across all study days the clinical EC50 value
(AUC0–24 3.23 lgh/mL and Cmin 0.05 lg/mL) determined
from the previous pharmacokinetic/pharmacodynamic
analysis of saquinavir monotherapy data in 84 patients by
several-fold [21]. Further, mean saquinavir C12 values in
this study exceeded those recommended in the US
Department of Health and Human Services (DHHS)
guidelines on antiretroviral treatment for adults and ado-
lescents (100–250 ng/mL) with drug-susceptible virus [22].
HIV RNA was collected across study days to evaluate
the effect of the modified saquinavir/ritonavir dosing
regimen when combined with two NRTIs on antiviral ac-
tivity in the treatment-naı¨ve patients. Continuous declines
in HIV RNA were observed in all treatment-naı¨ve patients
over the 2-week treatment duration. The mean decline in
viral load on day 14 following administration of the
modified saquinavir/ritonavir regimen observed in the
current study (–1.93 ± 0.28 log10 copies/mL) was com-
parable to the day 14 viral load decline reported in the
GEMINI phase III study evaluating the full saquinavir/ri-
tonavir dosing regimen (1000/100 mg BID) in a similar
patient population (-1.88; 95 % CI -2.0 to -1.8) [23, 24].
However, it is important to note that, although short-term
continuous declines in HIV RNA were observed and were
comparable to those obtained with standard doses in the
GEMINI study, the long-term efficacy of the modified
regimen was not evaluated. Adherence to antiretroviral
therapy has been correlated strongly with HIV viral sup-
pression and reduced rates of resistance [22, 25]. For most
patients who are adherent to therapy and who do not harbor
resistance mutations to the prescribed drugs, complete viral
suppression is generally achieved in 12–24 weeks [22].
The patients in the current study were treated at a single
study center, and study medication was administered by the
study staff while patients were in the study unit. Thus,
while a continuous decline in HIV RNA or viral load was
observed in all patients, it is likely that the modified
saquinavir/ritonavir regimen in combination with NRTIs
and adherence also contributed to HIV viral suppression
during the time of the study.
Safety results from the study indicated that oral
saquinavir/ritonavir 500/100 mg BID for the first week
followed by saquinavir/ritonavir 1000/100 mg BID in the
second week, in combination with two NRTIs, was gen-
erally well tolerated. Although nearly all of the patients
experienced AEs, most were mild or moderate in severity.
Results of laboratory examinations, vital signs assess-
ments, and ECGs did not reveal any clinically significant
changes. Mean changes over time in heart rate and RR,
PR, QRS, and QT intervals were small and not clinically
significant.
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In summary, results from this study demonstrated that the
modified saquinavir/ritonavir regimen reduced mean max-
imum DQTcFdense in the first week of treatment when
compared with historical data obtained with the standard
dose regimen in a different population of healthy volun-
teers enrolled in a TQT study; only 2/21 (9.5 %) patients
across all study days had maximum DQTcFdense C30 ms
and the maximum mean DQTcFdense remained below
10 ms across all study days. Saquinavir pharmacokinetic
parameters were lower than those observed on day 3 in the
TQT study in healthy volunteers, while day 14 saquinavir
exposures approached historical mean (and target expo-
sure) values for steady-state saquinavir exposures in HIV-
1-infected patients receiving full doses of saquinavir/ri-
tonavir. Continuous declines in HIV RNA were observed
in all treatment-naı¨ve patients receiving the modified
saquinavir/ritonavir dosing regimen over the 2-week
treatment period, suggesting HIV viral suppression during
the time of the study. No patient experienced virologic
breakthrough or rebound, so no resistance testing was
conducted. Safety results showed that saquinavir/ritonavir
regimens were well tolerated. Thus, treatment initiation
with the modified saquinavir/ritonavir regimen in treat-
ment-naı¨ve, HIV-1-infected patients starting de novo ri-
tonavir-boosted saquinavir treatment resulted in reduced
saquinavir exposure (Cmax and AUC) during the first week,
potentially mitigating or reducing QTc liability while
suppressing HIV RNA during the period of observation.
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